愛(ài)爾眼科醫(yī)院集團(tuán)是具有中國(guó)及全球范圍醫(yī)院規(guī)模和優(yōu)質(zhì)醫(yī)療能力的眼科醫(yī)療集團(tuán)，服務(wù)覆蓋亞洲、歐洲和北美洲，在中國(guó)內(nèi)地、歐洲、東南亞擁有3家上市公司(中國(guó)A股：愛(ài)爾眼科，300015;西班牙：CBAV;新加坡：40T)。目前在全球范圍內(nèi)開(kāi)設(shè)眼科醫(yī)院及中心達(dá)723家，其中中國(guó)內(nèi)地610家、中國(guó)香港7家、美國(guó)1家、歐洲93家、東南亞12家。2021年，中國(guó)內(nèi)地年門(mén)診量超1500萬(wàn)人次，手術(shù)量超100萬(wàn)臺(tái)，醫(yī)療服務(wù)網(wǎng)絡(luò)覆蓋全球近30億人口（注：愛(ài)爾眼科旗下機(jī)構(gòu)數(shù)量更新截至2021年12月31日，來(lái)源愛(ài)爾眼科醫(yī)院集團(tuán)股份有限公司《2021年度社會(huì)責(zé)任報(bào)告》）。

AIEREyeHospitalGroupisaleadingophthalmicmedicalgroup(eye-careserviceprovider)withdomesticandglobalfootprintandhigh-standardmedicalcarecapacity,servingpatientsacrossAsia,Europe,andNorthAmerica.AIERhasthreepublic-tradingcompanieslistedinChina,Europe,andSoutheastAsia,respectively(ShenzhenStockMarket:AIER,300015;SpainBME:CBAV;SingaporeSGX:40T).Wehavesofarestablished723ophthalmichospitalsandcentersacrosstheworld,including610hospitalsandcentersinmainlandChina,7inHongKong,China,1intheUnitedStates,90inEurope,and12inSoutheastAsia.In2021,weservedmorethan15millionoutpatientvisitsandpreformedover1millionsurgeriesinmainlandChina.Ourmedicalservicenetworkcoversapproximately3billionpeopleworldwide.

愛(ài)爾眼科始終堅(jiān)持以國(guó)內(nèi)發(fā)展為主線，國(guó)內(nèi)國(guó)際雙線并舉，共同進(jìn)步。在發(fā)展的過(guò)程中，致力于引進(jìn)和吸收國(guó)際同步的眼科技術(shù)與醫(yī)療管理理念，以專業(yè)化、規(guī)?；⒖茖W(xué)化為發(fā)展戰(zhàn)略，推動(dòng)中國(guó)眼科醫(yī)療事業(yè)的發(fā)展。通過(guò)不斷實(shí)踐，在充分吸收國(guó)際優(yōu)質(zhì)的醫(yī)療管理經(jīng)驗(yàn)的基礎(chǔ)上，成功探索出一套適應(yīng)中國(guó)國(guó)情和市場(chǎng)環(huán)境的眼科醫(yī)院連鎖經(jīng)營(yíng)管理模式——“分級(jí)連鎖”，充分發(fā)揮人才、技術(shù)和管理等方面的優(yōu)勢(shì)，提升診療質(zhì)量、完善醫(yī)療服務(wù)、優(yōu)化醫(yī)患溝通。

DomesticmarketisthecorebusinessofAIERandinternationalmarketplaysamoreandmoreimportantroleinourglobalstrategy.Wearecommittedtointroducingandabsorbingthecutting-edgetechnologyandadvancedmanagementconcepts,aswellastocontributingtotheevolutionofChina'sophthalmologymarket,inaspecialized,scaled-upandscientificway.

AIERhassuccessfullyexploredthebusinessmodelinlinewithChina’snationalandmarketconditionthroughcontinuouspractice-the“hierarchicalchain”-tofullyutilizeadvantagesintalent,technologyandmanagementsoastoachievebetterclinicaloutcome,toimproveservicestandardandtooptimizecommunicationbetweenpatientsandmedicalpersonnel.

科研創(chuàng)新、人才培養(yǎng)是長(zhǎng)遠(yuǎn)發(fā)展的基石，愛(ài)爾眼科不斷加大科研投入，大力支持開(kāi)展前沿性、原創(chuàng)性的眼科學(xué)術(shù)研究，全力推進(jìn)全球化平臺(tái)上的眼健康生態(tài)圈戰(zhàn)略。自2013年愛(ài)爾眼科與中南大學(xué)聯(lián)合成立中南大學(xué)愛(ài)爾眼科學(xué)院，正式開(kāi)啟校企合作的創(chuàng)新探索以來(lái)，陸續(xù)推動(dòng)了與湖北科技學(xué)院、武漢大學(xué)、暨南大學(xué)、安徽醫(yī)科大學(xué)、天津大學(xué)、四川大學(xué)等知名高校的戰(zhàn)略合作，充分發(fā)揮企業(yè)和高校的獨(dú)特優(yōu)勢(shì)，在醫(yī)院共建、人才培養(yǎng)、師資隊(duì)伍建設(shè)、教學(xué)科研等領(lǐng)域展開(kāi)深入合作，聯(lián)手共建眼科醫(yī)教研平臺(tái)，合力打造“名校+名企”典范，為社會(huì)培養(yǎng)更多的眼科醫(yī)學(xué)人才，真正地為中國(guó)眼科學(xué)和視覺(jué)科學(xué)的創(chuàng)新發(fā)展貢獻(xiàn)智慧與力量。

Scientificresearchinnovationandtalentcultivationarethecornerstonesoflong-termdevelopment.Wevigorouslysupportthedevelopmentoforiginalandcutting-edgescientificresearchandmakeourselvescommittedtocreatingaclosed-loopophthalmicecosystemonaglobalplatformbygraduallyincreasinginvestment.

SincethejointestablishmentofAIERSchoolofOphthalmologyofCentralSouthUniversitybyAIERandCentralSouthUniversityin2013,aninnovativeexplorationofschool-enterprisecooperationwasofficiallylaunched.AIERthensuccessivelypromotedstrategiccooperationwithwell-knownuniversities,suchasHubeiUniversityofScienceandTechnology,WuhanUniversity,JinanUniversity,AnhuiMedicalUniversity,TianjinUniversity,andSichuanUniversity,etc.

AIERandtheuniversitiesaresharingthesamegoaltobuildanintegratededucationandresearchplatformbyleveragingthestrengthsof“GoodCompany”and“FamousUniversity”throughin-depthcollaborationinareasofhospitalco-management,talentandfacultytraining,academicdevelopmentandscientificresearch,soastotrainexcellentophthalmictalentsforthecommunity,aswellastocontributeourwisdomandpowertotheevolutionoftheophthalmologyandvisionscienceinChina.

在此基礎(chǔ)上，愛(ài)爾眼科持續(xù)打造立體化科研平臺(tái)，截止目前已在全國(guó)范圍內(nèi)構(gòu)建起“八所、二站、二基地、三中心”的創(chuàng)新型科教研一體化平臺(tái)。“八所”：愛(ài)爾眼科研究所、愛(ài)爾眼視光研究所、愛(ài)爾角膜病研究所、愛(ài)爾屈光研究所、愛(ài)爾視網(wǎng)膜研究所、愛(ài)爾青光眼研究所、愛(ài)爾白內(nèi)障與人工晶狀體研究所、武漢愛(ài)爾眼科研究所。獲批設(shè)立“二站”：國(guó)家博士后科研工作站、湖南省院士專家工作站；“二基地”：湖南省眼視光國(guó)際科技合作基地、湖南省“海智計(jì)劃”工作基地；“三中心”：湖南省眼視光工程技術(shù)研究中心、湖南省眼表疾病臨床醫(yī)學(xué)研究中心、湖南省企業(yè)技術(shù)中心；聯(lián)合共建“愛(ài)爾眼科-中科院計(jì)算所數(shù)字眼科聯(lián)合實(shí)驗(yàn)室”等創(chuàng)新平臺(tái)。

Basedonthis,AIERcontinuedtocreateacomprehensivescientificresearchplatform.Uptonow,aninnovativeplatformintegratingscience,educationandresearch.“EightInstitutes,TwoStations,TwoBases,andThreeCenters”hasbeenestablishednationwide.

“EightInstitutes”referstoEyeInstitute,Optometry&VisualScienceInstitute,KeratoconusInstitute,RefractiveInstitute,RetinaInstitute,GlaucomaInstitute,CataractInstitute,andAIEROphthalmicResearchInstituteinWuhan;“TwoStations”referstoNationalPost-DoctoratesR&DWorkstationandAcademicianExpertHunanProvincialWorkstation,whichwasestablishedafterapproval;“TwoBases”referstoHunanInternationalOptometryScienceandTechnologyCooperationBaseandHOMEProgramworkbaseinHunanProvince;“ThreeCenters”referstoHunanOptometryEngineeringTechnologyResearchCenter,HunanOcularSurfaceDiseaseClinicalMedicineResearchCenter,andHunanEnterpriseTechnologyCenter;meanwhilevariousinnovativeplatformssuchas“AIER-ICTDigitalOphthalmologyJointLaboratory”werejointlyestablished.

上市十年之際，愛(ài)爾眼科以“創(chuàng)新驅(qū)動(dòng)，科技愛(ài)爾”作為指導(dǎo)方針，提出三大戰(zhàn)略目標(biāo)。

Onthe10thAnniversaryoflisting,AIERtook“InnovationDrivenandTechnologyEmpowered”astheguidelineandproposedthreestrategicgoals.Thefirstgoalistoexpandthemedicalservicenetworkintovasturbanandruralareas,enablingpatientstoexperienceconvenientandhigh-qualityophthalmicmedicalservice,implementingthestrategyof“HealthyChina”.ThesecondgoalistocontinuouslyimproveophthalmicmedicaltechnologyinChinaandtoberecognizedasworld-levelexcellencebybuildingupworld-classandnational-levelophthalmicmedicalcenter.Thelastbutnottheleastgoalistopromoteadvancementofhumanophthalmologyandvisualsciencethroughglobalfootprintaswellascoordinateddevelopmentofmedicine,education,research,productionandinvestment.

在十九年的創(chuàng)業(yè)發(fā)展歷程中，愛(ài)爾眼科凝聚和培養(yǎng)了一批經(jīng)驗(yàn)豐富、具有開(kāi)拓創(chuàng)新精神的管理團(tuán)隊(duì)和醫(yī)術(shù)精良、治學(xué)嚴(yán)謹(jǐn)?shù)难劭茖＜液歪t(yī)生團(tuán)隊(duì)。截至目前，愛(ài)爾眼科醫(yī)院集團(tuán)及旗下全球員工總數(shù)達(dá)50000余人，其中眼科醫(yī)生及視光師總數(shù)(含海外)9000余人，包括一大批博士生導(dǎo)師、碩士生導(dǎo)師、博士、博士后、留學(xué)歐美的學(xué)者以及臨床經(jīng)驗(yàn)豐富的核心專家。

Throughthepast19-yeargrowthandexpansion,AIERhasattractedandcultivatedagroupofexperiencedmanagementteamwithinnovativespirit,aswellasateamofwell-trainedophthalmologistsanddoctorswithexcellentmedicalskillsandrigorousscholarship.Atpresent,AIERhasmorethan50,000employeesworldwide.Amongthem,9,000areophthalmologistsandoptometrists(includingdomesticandoverseas),withabiggroupofdoctoralsupervisors,mastersupervisors,doctors,post-doctors,overseascholars,andevencoreexpertswithextensiveclinicalexperiences.

愛(ài)爾眼科的發(fā)展壯大始終以“使所有人，無(wú)論貧窮富裕，都享有眼健康的權(quán)利”為初心和使命，致力于全人類的光明事業(yè)，堅(jiān)持“以患者為中心”，追求社會(huì)責(zé)任和自身發(fā)展的和諧統(tǒng)一。通過(guò)開(kāi)創(chuàng)性的“交叉補(bǔ)貼”模式，在為患者提供更高品質(zhì)的眼科醫(yī)療服務(wù)的同時(shí)，開(kāi)展防盲治盲工作、投身社會(huì)公益、幫助弱勢(shì)群體，積極聯(lián)合社會(huì)各界力量，推動(dòng)中國(guó)防盲事業(yè)乃至國(guó)民眼健康事業(yè)的發(fā)展。2018年、2020年蟬聯(lián)第十屆、第十一屆中國(guó)政府榮譽(yù)慈善獎(jiǎng)項(xiàng)“中華慈善獎(jiǎng)”、榮獲中國(guó)公益年會(huì)“中國(guó)公益企業(yè)獎(jiǎng)”、“湖南慈善獎(jiǎng)”等榮譽(yù)。同時(shí)積極響應(yīng)國(guó)家號(hào)召，作為中國(guó)代表企業(yè)牽頭參與“一帶一路光明行”、“湄公河光明行”等公益活動(dòng)，獲得組織者、受援國(guó)政府和患者的高度好評(píng)，逐步發(fā)展成為全球慈善公益活動(dòng)的一張名片。

ThegrowthofAIERalwaysstickstotheoriginalintentionandmissionof“Enablingeveryone,nomatterrichorpoor,hastherighttoeyehealth”.Wearecommittedtothebrightfutureofallhumanbeings,insistingon“patient-oriented”principle,andpursuingtheharmoniousunityofsocialresponsibilityandself-development.Byadoptingthepioneering“CrossSubsidyModel”,whileofferingourpatientshigher-qualityophthalmicmedicalservice,AIERalsocomprehensivelycarriesoutblindnesspreventionandtreatment,devotestopublicwelfare,helpsvulnerablegroups,andactivelyunitesallforcesfromsociety,promotingthecomprehensivedevelopmentofChina’sblindnesspreventionandeventheeyehealthcareerofcitizens.In2018and2020,AIERwasawardedthe10thandthe11th“ChinaCharityAward”byChineseGovernment.Besides,wewerealsoawardedmanyotherhonors,suchas“ChinaPublicWelfareEnterpriseAward”,“BestSociallyResponsiblePublicCompany”,and“HunanCharityAward”,etc.Moreover,AIERrespondedpositivelytothenationalappealandtooktheleadindifferentpublicbenefitactivitiessuchas“TheBeltandRoadBrightnessCampaign”and“MekongBrightnessCampaign”,winningunanimouspraisefromorganizers,aidrecipientgovernmentsandpatients.Inthisway,AIERhasbeengraduallyregardedasarepresentativeofglobalphilanthropyactivities.

AIERhasbeenratedas“Top10MostValuedPublicCompanyinChina”byauthoritativeinstitutionsformultipleconsecutiveyears.Wewonthe“ChinaSpectrumAward”ofChinaBrandFestivalconsecutivelyandmanyotherhonors,including“BestSustainableInvestmentValueAward”,“ChinesePublicCompanyBestShareholderReturnAward”,and“ChinesePublicCompanyIndustrialContributionAward”,etc.Atthesametime,AIERwasalsosuccessfullyselectedasCSI300IndexStockandMSCIChinaIndexConstituentStock,etc.

微信訂閱愛(ài)爾眼科
請(qǐng)關(guān)注公眾號(hào)：aierhospital，愛(ài)眼護(hù)眼早知道。